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Edited by Sandro SonninoAbstract SH2 domain containing inositol polyphosphate 5-
phosphatase (SHIP2) dephosphorylates phosphatidylinositol
3,4,5-trisphosphate (PtdIns(3,4,5)P3) into phosphatidylinositol
3,4-bisphosphate (PtdIns(3,4)P2). SHIP2 knock-out mice
demonstrated that SHIP2 acts as a negative regulator of insulin
cascade in vivo. Our two-hybrid study showed that SHIP2
interacts with c-Cbl associated protein (CAP) and c-Cbl,
implicated in the insulin signaling. As some proteins implicated
in insulin signaling, like insulin receptor, CAP, c-Cbl or TC10,
were reported to localize in lipid rafts, we addressed the same
question for SHIP2. SHIP2 was detected in the non-raft fraction
in CHO-IR, C2C12 myotubes and 3T3-L1 adipocytes except
when it is overexpressed in CHO-IR, where we detected SHIP2
in the raft fraction.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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SH2 domain containing inositol 5-phosphatase (SHIP2),
like SHIP1, is a member of the type II polyphosphate 5-
phosphatase family. It contains SH2, proline-rich, NPXY and
SAM protein–protein interaction domains and is able to
dephosphorylate phosphatidylinositol 3,4,5-trisphosphate
(PtdIns(3,4,5)P3) into phosphatidylinositol 3,4-bisphosphate
(PtdIns(3,4)P2) [1]. Compared to SHIP1 that is restricted to
hematopoietic cells, SHIP2 is widely expressed in a wide range
of tissues [2]. SHIP2 is phosphorylated in response to growth
factors [3] and by insulin in CHO-IR and 3T3-L1 [4,5]. Nev-
ertheless, the role of the phosphorylation of SHIP2 is not well
understood. It does not seem to modulate its 5-phosphatase
activity but rather its interaction with partners [6]. Data from
knock-out mice have identiﬁed SHIP2 as a critical and essen-
tial negative regulator of insulin signaling [7]. SHIP2 knock-
out mice show increased sensitivity to insulin and die soon
after birth. Heterozygous adult mice have increased glucose
tolerance and insulin sensitivity associated with an increased* Corresponding authors. Fax: +32-2-555-46-55.
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synthesis in skeletal muscle [7].
Insulin, via phosphatidyl inositol 3-kinase (PI3-K) activa-
tion, is known to be important for exerting a variety of met-
abolic actions (for review, see [8]). By dephosphorylating
PtdIns(3,4,5)P3 into PtdIns(3,4)P2, SHIP2 regulates negatively
PI3-K pathway. Its overexpression in 3T3-L1 adipocytes in-
hibited insulin-induced activation of Akt/PKB and decreased
Glut4 translocation [9]. In the same way, it has been reported
that insulin induced Glut4 translocation can also be negatively
regulated by expression of SHIP1 [10]. By a two-hybrid study,
we have recently shown the interaction between SHIP2, c-Cbl
associated protein (CAP) and c-Cbl, providing a potential
molecular link between SHIP2 and the insulin cascade [11].
Lipid rafts are described as subdomains of the plasma
membrane that contain high concentration of cholesterol and
glycosphingolipids. This particular composition can form a
liquid-ordered phase which is resistant to some detergent sol-
ubilization. Caveolae, that were originally identiﬁed as ﬂask-
shaped invagination of the plasma membrane in endothelial
and epithelial cells, can be viewed as a subset of lipid rafts.
They are distinguished from lipid rafts by the presence of the
cholesterol binding protein caveolin and are abundant in en-
dothelia, muscles cell types, adipocytes and ﬁbroblasts. A va-
riety of proteins have been shown to partition into caveolae
and lipid rafts (for review, see [12]). These microdomains can
be isolated on the basis of their resistance to solubilization in
non-ionic detergent (Triton X-100) at 4 C and their low
density in sucrose or OptiPrep gradients [13].
Stimulation of the insulin receptor by insulin leads to the
activation of several pathways. The major one implicates
the IRS proteins, activating the PI3-K. Insulin also stimulates
the MAPK pathway via Shc and Gab-1 [14] and the small G-
protein TC10 [15]. A possible role for caveolae and caveolin in
insulin signaling was suggested by the fact that caveolin-1
becomes phosphorylated upon insulin stimulation in 3T3-L1
[16]. Several laboratories have localized elements of the insulin
cascade in caveolae or rafts, including the insulin receptor it-
self, in 3T3-L1 adipocytes [17]. Furthermore, insulin receptor
co-immunoprecipitates with caveolin-1 in freshly isolated rat
adipocytes [18] and cholesterol depletion with b-cyclodextrine
inhibited insulin-stimulated glucose uptake [19]. CAP, c-Cbl,
TC10 and ﬂotillin-1, important proteins to stimulate the in-
sulin-induced Glut4 translocation to the plasma membrane,
are described as present in the lipid rafts [20–23]. Here, we
report by a detergent-based method of raft puriﬁcation that
endogenous SHIP2 is not observed in the lipid raft in CHO-IR
cells, in C2C12 myotubes or 3T3-L1 adipocytes.blished by Elsevier B.V. All rights reserved.
Fig. 1. Western blot analysis of caveolin (caveolae marker) and adap-
tin-b (clathrin-associated membranes marker) distribution. OptiPrep
density gradient fractions were prepared from SHIP2 transfected CHO-
IR in 1% Triton X-100 (A), or from wt CHO-IR (B), C2C12 (C) or 3T3-
L1 (D) in 0.5% Triton X-100 cells with (+ins) or without ()ins) insulin
stimulation 100 nM for 5 min. Equal volumes of OptiPrep density
gradient fraction were concentrated, subjected to 13% SDS–PAGE and
blotted. Blots were ﬁrst incubated with the mouse monoclonal adaptin-
b antibody and men reprobed with the rabbit polyclonal caveolin
antibody.
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2.1. Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM, 4.5 g/l glucose),
streptomycin/penicillin, fungizone, fetal bovine serum, horse serum
and calf serum were obtained from Gibco (Paisley, UK). Bovine se-
rum albumin, bovine insulin, 3-isobutyl-1-methylxanthine (IBMX),
dexamethasone and Triton X-100 were purchased from Sigma (St.
Louis, MO, USA). Protease inhibitors cocktail was from Roche
(Mannheim, Germany). OptiPrep 60% (w/v) in water was obtained
from Axis-Shield (Oslo, Norway). Mouse monoclonal antibodies
against adaptin-b (clone 74), ﬂotillin-2 (clone 29) and caveolin-1
(clone 2297) and rabbit polyclonal antibodies against caveolin and the
insulin receptor b-subunit were purchased from Transduction Lab
(Erembodegem, Belgium). Rabbit polyclonal antibody against CAP
was from Upstate Biotechnology (Veenendaal, The Netherlands).
Mouse monoclonal antibody against c-Cbl (clone A-9) was from
Santa Cruz Biotechnology, Inc. The rabbit polyclonal antibody
against SHIP2 was provided by C. Erneux and has been previously
reported [24]. The mouse monoclonal anti-HA antibody was from
Roche (Mannheim, Germany) and the mouse monoclonal anti-His
antibody was from Clontech (Palo Alto, CA).
2.2. Cell culture
CHO-IR cells were maintained in Ham’s F12 supplemented with
fetal bovine serum 10%, 100 U/ml penicillin and 100 mg/ml strepto-
mycin, fungizone 2.5 lg/ml and G-418 0.5% in 5% CO2/humidiﬁed
atmosphere at 37 C. C2C12 cells were maintained in DMEM sup-
plemented with fetal bovine serum 10%, 100 U/ml penicillin and 100
mg/ml streptomycin and fungizone 2.5 lg/ml in 5% CO2/humidiﬁed
atmosphere at 37 C. After conﬂuence, they were diﬀerentiated with
2% horse serum for three days. 3T3-L1 ﬁbroblasts, a kind gift of
doctor J. Pairault (Paris), were cultured in DMEM supplemented with
10% calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin in 8%
CO2/humidiﬁed atmosphere at 37 C. Diﬀerentiation to adipocytes was
induced 2 days post-conﬂuence by incubating the cells in DMEM
supplemented with fetal bovine serum 10%, 100 U/ml penicillin and
100 mg/ml streptomycin, 160 nM insulin, 0.25 lM dexamethasone and
100 lM IBMX for 2 days. Cells were maintained in the same medium
without dexamethasone and IBMX and used between day 7 and 11
following diﬀerentiation.
2.3. Preparation of detergent-resistant membranes by OptiPrep gradient
centrifugation
Lipid rafts were isolated from CHO-IR, 3T3-L1 adipocytes and
C2C12 myotubes using a modiﬁcation of the protocol of Tansey et al.
[25]. CHO-IR were transfected using Superfect (Invitrogen, Mere-
lbeke, Belgium) with the His-tagged SHIP2 and the HA-tagged CAP
in pcDNA3. 3T3-L1 and C2C12 cells were untransfected. Before the
stimulation with insulin, the cells were serum starved for 16 h. The
cells were rinsed twice with ice cold PBS, lysed and scraped in 400 ll
TEN buﬀer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA,
protease inhibitors and Triton X-100, 0.5% or 1%). The lysates were
homogenized by passage through a 21-gauge needle 10 times followed
by centrifugation at 800· g, for 10 min after 15 min solubilization. The
supernatant was adjusted to 35% (v/v) OptiPrep by adding 585 ll of
60% stock solution of OptiPrep, transferred to the bottom of a cen-
trifuge tube and overlayed successively with 8 ml of 30% OptiPrep
(diluted with 0.5 TEN buﬀer) and 1 ml of TNE buﬀer. After cen-
trifugation at 197 000· g for 4 h (SW41, 40 000 rpm), 1 ml fractions
were collected from the top of the gradient (designated fractions
number 1 (top) to 10 (bottom)). Protein samples of equal volumes
taken from each fraction were concentrated with StrataClean (Strat-
agene), resuspended in Laemmli buﬀer and boiled for 5 min.
2.4. Western blotting experiments
Protein samples from OptiPrep gradient fractions were resolved by
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and blotted
onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Ger-
many), which were incubated in 5% non-fat dry milk dissolved in
TBSN buﬀer (20 mM Tris–HCl, pH 7.6, 140 mM NaCl, 0.05% Non-
idet P-40), for 1 h at room temperature, to block the non-speciﬁc sites.
Incubations with primary antibodies were carried out for 2 h at room
temperature. After several washings, the membranes were incubated
for 1 h with the respective peroxidase-conjugated secondary antibody(Amersham, Bucks, UK) diluted in TBSN. The membranes then un-
derwent another extensive washing in TBSN and the bound antibodies
were detected using a chemiluminescence method (Western Lighting,
NEN, Boston, USA).3. Results
3.1. Insulin receptor is observed in lipid rafts in CHO-IR,
C2C12 myotubes and 3T3-L1 adipocytes
CHO-IR cells, diﬀerentiated C2C12 and 3T3-L1 cells were
solubilized with Triton X-100 at 4 C for 15 min. As the de-
tergent concentration seems to be of crucial importance to
detect the insulin receptor in the lipid rafts [26], we tested two
concentrations (0.5% or 1%) of Triton X-100. The lysate was
loaded on an OptiPrep gradient and centrifuged. One milliliter
fractions from the top of the tube were collected and analyzed
for rafts and non-rafts markers (Fig. 1). Caveolin or ﬂotillin,
known to be associated with lipid rafts [22] and b-adaptin, a
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detect, respectively, the raft (fraction 2) and non-raft fractions
(fraction 10) in our gradients. The results on the three types of
cells generally reproduce the literature on other cells: caveolin
mostly in rafts, adaptin mostly in non-raft fraction and ﬂotillin
in both but mostly in non-raft fraction. In 3T3-L1, caveolin is
very abundant, spilling over to other fraction but not to the
non-raft fraction. In each cell type, insulin receptor is detected
in both fractions (Fig. 2A), as reported by Huo and Kimura
who have isolated the lipid rafts by detergent-free methods
[27,28]. Although no eﬀect of insulin on the distribution of the
IR was previously described in 3T3-L1 adipocytes [17], we
observed most of the time that IR level is lower in raft fraction
after insulin stimulation. This could be due to the endocytosis
of the receptor which follows stimulation. On the other hand,
in contrast to the results published by Gustavsson et al. [17]
and others [16,29], we do not solubilize completely the IR by
using a detergent-based method for lipid rafts preparation;
even with 1% Triton X-100, we still observed the IR in the raft
fraction in adipocytes (Fig. 2B).
3.2. Endogenous SHIP2 does not localize in lipid rafts of
CHO-IR, diﬀerentiated C2C12 cells or 3T3-L1 adipocytes
The CAP/c-Cbl complex was shown to be present in lipid
rafts in adipocytes [20] and SHIP2 was shown to associate to
CAP and c-Cbl in CHO-IR [11]. We therefore addressed the
question whether SHIP2 localizes in these caveolin enriched
detergent resistant fractions. CHO-IR cells were co-transfected
with HA-tagged CAP and His-tagged SHIP2, and solubilized
with 1% Triton X-100. Non-transfected CHO-IR, C2C12 or
3T3-L1 cells were solubilized with 0.5% Triton X-100. OptiPrepFig. 2. Western blot analysis of insulin receptor distribution in 0.5%
Triton X-100/OptiPrep density gradient. (A) Fraction 2 (raft fraction)
and 10 (non-raft fraction) were prepared from C2C12 or 3T3-L1 cells
stimulated (+ins) or not ()ins) by insulin 100 nM for 5 min. (B) One
percent Triton X-100/OptiPrep density gradient fraction 2 (raft frac-
tion) and 1.0 (non-raft fraction) were prepared from SHIP2 transfected
CHO-IR or 3T3-L1 cells stimulated (+ins) or not ()ins) by insulin 100
nM for 5 min.gradients were performed and each gradient was analyzed for
rafts and non-rafts markers (as in Fig. 1). In SHIP2-transfected
CHO-IR, SHIP2 was detected in both raft and non-raft frac-
tions, independently of insulin stimulation of the cells
(Fig. 3A). On the other hand, endogenous SHIP2 was only
observed in the non-raft fraction in non-transfected CHO-IR
cells, in C2C12 myotubes and in 3T3-L1 adipocytes (Fig. 3B).
We have also tested the presence of SHIP2 in the raft fraction
after 1 and 15 min insulin stimulation and we cannot detect
SHIP2 in the raft fraction (Fig. 3C).
3.3. Detection of CAP and c-Cbl in lipid rafts in 3T3-L1
adipocytes
As CAP and c-Cbl were reported to be recruited to the lipid
rafts following insulin stimulation [20], we wanted to test
whether CAP and c-Cbl could be detected in the lipid rafts of
3T3-L1 (Fig. 4). Although the major part of endogenous CAP
was detected in the non-lipid raft fraction, we showed that a
small part localizes in the raft fraction, independently of in-
sulin stimulation. We cannot detect endogenous c-Cbl in this
fraction contrary to Baumann et al. [20] who detected it with a
non-detergent-based method.Fig. 3. (A) Western blot analysis of SHIP2 distribution. One percent
Triton X-100/OptiPrep density gradient fraction 2 (raft fraction) to 10
(non-raft fraction) were prepared from pCDNA3.his-SHIP2 trans-
fected CHO-IR cells and stimulated (+ins) or not ()ins) by insulin 100
nM for 5 min. (B) About 0.5% Triton X-100/OptiPrep density gradient
fraction 2 (raft fraction) and/to 10 (non-raft fraction) prepared from
CHO-IR, C2C12 or 3T3-L1 cells stimulated (+ins) or not ()ins) by
insulin 100 nM for 5 min. (C) Western blot analysis of SHIP2 in 0.5%
Triton X-100/OptiPrep density gradient fraction 2 (raft fraction) and
10 (non-raft fraction) prepared from 3T3-L1 cells and stimulated for 1,
5 and 15 min by 100 nM insulin.
Fig. 4. Western blot analysis of c-Cbl or CAP in 0.5% Triton X-100/
OptiPrep density gradient fraction 2 (raft fraction) and 10 (non-raft
fraction) prepared from diﬀerentiated 3T3-L1 cells stimulated (+ins) or
not ()ins) by insulin 100 nM for 5 min.
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SHIP2 was demonstrated to be involved in insulin signaling
by knock-out mice data [7] and to be able to interact with CAP
and c-Cbl by our previous study [11]. Considering Saltiel,
Pessin and co-workers work about the CAP/c-Cbl pathway
and the fact that SHIP1 was detected in lipid rafts [30,31], we
addressed the question whether SHIP2 localizes in caveolae.
We used a detergent-based method to isolate raft subdomains
of CHO-IR, C2C12 myotubes and 3T3-L1 adipocytes and
analyzed the presence of SHIP2, IR, CAP and c-Cbl by
Western blotting. A small part of IR and CAP was detected in
the raft fraction, but we cannot detect either SHIP2 or c-Cbl in
the caveolin enriched fraction. It seems unlikely that SHIP2
could be solubilized from the rafts fraction by Triton X-100 as
described for IR as we can detect the transfected SHIP2 in the
lipid rafts of CHO-IR. The presence of SHIP2 in raft structure
of transfected CHO-IR cells could be due to overexpression of
the protein which could escape from its correct localization.
We thus showed here that SHIP2, although implicated in in-
sulin signaling, is not found in the lipid rafts.
The arguments for lipid rafts existence and function rely on
indirect methods such as eﬀect of cholesterol depletion and use
of non-ionic detergents extraction and a number of recent
studies have revealed that these methods could create rafts by
themselves [32,33]. These studies have produced conﬂicting
results [32,33]. Lipid rafts, enriched in cholesterol and sphin-
golipids, are diﬃcult to visualize in living cells. However, rafts
were suggested to be implicated in many cellular processes such
as signaling, apoptosis, ion channel function, and it is now
widely accepted that membrane proteins and lipids can be or-
ganized into microdomains in eukaryotic cell membranes (for
recent reviews, see [12,34]). Many studies have focused on
classifying protein as raft or non-rafts proteins and determining
the size of these microdomains [32,35]. On the other hand, data
about the presence of certain proteins in the lipid rafts are
controversial. For example, depending on the method used, IR
localizes in the lipid rafts or not [16,17,29]. Although several
studies showed that the components of CAP/c-Cbl and TC10
cascade localize in the caveolae lipid rafts, a recent study ana-
lyzed the lipid rafts content by immunoisolation of rat adipo-
cytes caveolae and found no evidence for association of insulin
receptor with caveolin by co-immunoprecipitation or by im-
munoisolation [36]. Thus, it is not clear if the proteins involved
in insulin signaling are in the lipid rafts. Pessin, Saltiel and
colleagues proposed a new pathway for insulin signaling:stimulation of the IR, by insulin, would enhance phosphory-
lation of c-Cbl through the adapter protein APS. The c-Cbl/
CAP complex would then dissociate from the receptor and
migrate to lipid rafts to recruit CrkII and activate TC10 via the
GTPase activating protein C3G. Although this model is ap-
pealing, nothing is known on how c-Cbl moves to the lipid rafts
after phosphorylation. If insulin receptor itself is in the lipid
rafts, the phosphorylation of c-Cbl would happen there; how-
ever, c-Cbl was not observed in rafts in the absence of insulin
[20]. CAP itself complexes with c-Cbl even in the absence of
insulin [37] and yet CAP localizes in the lipid raft independently
of insulin stimulation [20]. These facts are not compatible with
the model and our understanding of how the insulin receptor
activates the CAP/c-Cbl cascade has still to be enlarged. De-
velopment of methods like immunoisolation [36] will perhaps
help us in resolving these questions.
Several studies demonstrated that SHIP2 is implicated in
insulin signaling [7,9]. Insulin-stimulated glucose disposal in
skeletal muscles, one of the major sites of insulin action [38],
account for more than 80% of postprandial glucose uptake [39],
localizing GLUT4 to the sarcolemma. It was demonstrated that
in these cells, SHIP2 co-localizes at Z-lines and the sarcolemma
with ﬁlamin, an actin binding protein implicated in cell mi-
gration [40]. SHIP2 could be implicated in several processes in
the cell, and only an undetectable part could interact with CAP,
in the lipid rafts. By its interaction with ﬁlamin, SHIP2 could
localize near PtdIns(3,4,5)P3 and regulate Glut4 translocation.
As the main role of SHIP2 could be to decrease PtdIns(3,4,5)P3
produced by the PI3-K, SHIP2 has to localize near the PI3-K
which does not reside in the lipid rafts in 3T3-L1 adipocytes
[28]. The fact that CAP and c-Cbl were found, for the major
part at least, outside of cavolae could explain that they can
interact with SHIP2. Whether lipid rafts are important for in-
sulin signaling in muscles and adipocytes is not yet clearly
demonstrated and the diﬀerent studies are contradictory, but
the data we present here demonstrate that with presently
available methodology about rafts puriﬁcation, SHIP2 does
not appear to be recruited there.
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